Insmed’s lead asset ALIS poses compelling prospects for commercial success in the U.S.
This hedge fund guru has made the right call on these three booming stocks.
These 3 pharmas are rising on positive clinical results data
Great news from ALIS phase 3 sends Insmed stock into orbit
Insmed Incorporated (NASDAQ:INSM) reported financial results for the quarter ended September 30, 2016 and provided a business update. Business Update Achieved enrollment objective …
Insmed Incorporated (NASDAQ:INSM) announced the online publication of data from its phase 2 study of ARIKAYCE™ (liposomal amikacin for inhalation or LAI) in the …
Insmed Incorporated (NASDAQ:INSM) announced a licensing agreement with AstraZeneca (NYSE:AZN) for global exclusive rights to AZD7986, a novel oral inhibitor of dipeptidyl peptidase I …
Insmed Incorporated (NASDAQ:INSM) announced the appointment of Roger Adsett as chief commercial officer. Mr.
Advaxis, Inc. In a research report released today, H.
Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced that it has withdrawn its …